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Abstract: Ropinirole prolonged release is a once-daily, 24-hour formulation of ropinirole, a 
non-ergot dopamine agonist. It is approved as monotherapy and as an adjunct to levodopa in 
the treatment of Parkinson’s disease (PD). Several potential advantages of ropinirole prolonged 
release compared to the immediate release formulation include maintaining more consistent 
dopaminergic activity with steadier plasma levels, increased tolerability, greater compliance from 
a simpler once-daily dosing regimen and ease in dose titration. In a randomized, double-blind, 
non-inferiority, crossover study, ropinirole prolonged release was shown to have comparable 
efﬁ  cacy and tolerability to immediate release ropinirole in early PD patients, with signiﬁ  cantly 
greater compliance. Subjects were converted overnight between ropinirole formulations without 
loss of efﬁ  cacy and with good tolerability. In a randomized, double-blind, placebo-controlled 
study in advanced PD, daily “off” time was reduced by an average of 2.1 hours with ropinirole 
prolonged release compared to 0.4 hours with placebo. Patients on ropinirole prolonged release 
were also more likely to require less daily levodopa. Ropinirole prolonged release is well tolerated 
with a similar adverse effect proﬁ  le to other non-ergot dopamine agonists. The most common 
adverse effects include dyskinesia, nausea, dizziness, hallucinations, somnolence, abdominal pain 
or discomfort and orthostatic hypotension. Ropinirole prolonged release is a safe and effective 
treatment option for both early and advanced PD. This manuscript brieﬂ  y reviews the current 
pharmacological treatment options for PD and provides a more detailed review of the currently 
available data regarding ropinirole prolonged release as a treatment option for PD.
Keywords: ropinirole prolonged release, ropinirole PR, dopamine agonist, Parkinson’s disease, 
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Introduction
Parkinson’s disease (PD) is a progressive neurological disorder with the primary 
symptoms of bradykinesia, tremor, and rigidity as well as postural instability as the 
disease advances. Although the average age of onset is 60 years, adults of all ages can 
be diagnosed with PD. It is estimated that the prevalence of PD in the United States 
(US) is approximately one million persons1 and approximately 50,000 new cases are 
diagnosed each year.2 The lifetime risk of developing PD is estimated to be 2.0% for 
men and 1.3% for women.3
At the time of diagnosis, the initiation of treatment is based on several factors 
such as age, other medical conditions, cognitive and psychiatric status, employment, 
social situation and severity of symptoms. Treatment is generally initiated when the 
symptoms of PD are bothersome to the patient or interfering with the patient’s daily 
functioning. There are currently several treatment options available for PD that can 
lessen physical disability, reduce signs and symptoms of the disease and improve 
overall quality of life.4–7 These treatments include carbidopa/levodopa, monoamine 
oxidase type B (MAO-B) inhibitors, dopamine agonists, catechol-O-methyltransferase 
(COMT) inhibitors, anticholinergics, and amantadine (Table 1). This review will brieﬂ  y 
discuss the treatment options available for PD and will focus on ropinirole prolonged Clinical Interventions in Aging 2009:4 180
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release, a once-daily non-ergot dopamine agonist approved 
by the US Food and Drug Administration (FDA) in 2008.
Treatment of early Parkinson’s 
disease
Carbidopa/levodopa is the most effective treatment option 
for PD and at some point during the disease course will be 
required by almost all PD patients.8 However, even early 
in the disease course, carbidopa/levodopa can lead to the 
development of motor complications such as motor ﬂ  uctua-
tions and dyskinesia.9 Motor ﬂ  uctuations generally initially 
present as a re-emergence of PD symptoms at the end of a 
given dose, prior to the scheduled intake of the next dose 
often referred to as end of dose wearing off. As the disease 
progresses, “on/off” ﬂ  uctuations may occur in which the 
patient ﬂ  uctuates between “on” periods when the medica-
tion is controlling PD symptoms and “off” periods when 
symptoms are not controlled. Initially these ﬂ  uctuations tend 
to be predictable and progress to unpredictable ﬂ  uctuations 
between the “on” and “off” states. It has been suggested that 
motor ﬂ  uctuations may be a result of pulsatile stimulation 
of dopamine receptors due to the short duration response 
of multiple daily doses of oral levodopa.10 Dyskinesia are 
involuntary wiggling or dance-like movements that most 
commonly occur at peak levodopa blood concentrations.8 
Risk factors for the development of levodopa-induced motor 
complications include longer disease duration, longer dura-
tion of levodopa therapy, higher doses of levodopa, often 
over 300 mg/day,9 greater disease severity and younger age 
of disease onset.11 More speciﬁ  cally, it has been demonstrated 
that a higher daily levodopa dose per kilogram body weight 
may be a stronger predictor of the development of dyskine-
sia than the absolute amount of daily levodopa.12 Given the 
potential for levodopa to cause motor complications, it is a 
common treatment strategy to initiate therapy with an alter-
nate medication and add levodopa later in the disease course 
as symptoms become more severe.8 MAO-B inhibitors and 
dopamine agonists are commonly used as initial treatment 
options for PD.4,6
MAO-B metabolizes dopamine, therefore, MAO-B 
inhibitors, selegiline and rasagiline, block the MAO-B 
enzyme resulting in reduced metabolism of dopamine and 
hence more dopamine in the brain. Although only approved 
as an adjunctive treatment to levodopa in the US, selegiline, 
at doses of 5 mg in the morning and afternoon, has been 
shown to have mild beneﬁ  t in the treatment of early PD.4 
Selegiline is metabolized to amphetamine and methamphet-
amine metabolites which can lead to adverse effects such 
as confusion and hallucinations. Rasagiline is approved 
for the treatment of early PD at a dose of 1 mg taken once 
daily and results in a mild improvement in PD symptoms. 
It is metabolized to aminoindan rather than amphetamine 
and methamphetamine metabolites and therefore does not 
have the related side effects seen with selegiline and overall 
has minimal adverse effects.6 In addition, in a delayed start 
study design with rasagiline it was reported that patients 
who started rasagiline earlier had better Uniﬁ  ed Parkinson’s 
Disease Rating Scale (UPDRS) scores at one year compared 
to patients who initiated with placebo and started rasagiline 
6 months later.13
Dopamine agonists directly stimulate the post-synaptic 
dopamine receptors. The non-ergot dopamine agonists, rop-
inirole and pramipexole, are currently the most commonly 
used. They have both been shown to be efﬁ  cacious in the 
treatment of early PD and to delay the development of motor 
complications when compared to levodopa.14,15 Pramipex-
ole is generally dosed three times daily and slowly titrated 
over several weeks to a maximum daily dosage of 4.5 mg. 
Table 1 Available pharmacological treatment options for Parkinson’s 
disease
Pharmacological treatments for Parkinson’s disease
Dopamine precursor
 Carbidopa/levodopa  (Sinemet®, Parcopa®, generics)
  Carbidopa/levodopa extended release (Sinemet CR®, generics)
Dopamine agonists
 Ropinirole  (Requip®, generic)
  Ropinirole prolonged release (Requip XL®)
 Pramipexole  (Mirapex®)
 Rotigotine  patch  (Neupro®)
 Apomorphine  injections  (Apokyn®)
MAO-B inhibitors
 Rasagiline  (Azilect®)
 Selegiline  (Eldepryl®)
  Orally disintegrating selegiline (Zelapar®)
COMT inhibitors
 Entacapone  (Comtan®)
 Carbidopa/levodopa/entacapone  (Stalevo®)
 Tolcapone  (Tasmar®)
Anticholinergics
 Benztropine  (Cogentin®)
 Trihexyphenidyl  (Artane®)
Antiglutamatergics
 Amantadine  (Symmetrel®)
Abbreviations: COMT, catechol-O-methyltransferase; MAO-B, monoamine oxidase 
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Ropinirole is also generally given three times daily and 
slowly titrated over several weeks to a maximum dose of 
24 mg. In general dopamine agonists are considered to be 
less efﬁ  cacious than levodopa.6 Dopamine agonists have 
an increased risk of adverse effects compared to levodopa, 
namely, somnolence, hallucinations, edema and impulse con-
trol disorders.4,16 Rotigotine is a dopamine agonist formulated 
as a continuous release transdermal patch approved for the 
treatment of early PD in the US at doses up to 6 mg/24 hours; 
however, it was recalled by the FDA in 2008 after crystal-
lization of the patch release system led to unpredictable 
drug release and variable plasma drug levels.17 Rotigotine 
is available in countries outside the US at daily dosages up 
to 8 mg/24 hours for early PD. The older, ergot-derived 
dopamine agonists, bromocriptine and pergolide as well as 
cabergoline which is not approved as a treatment for PD in 
the US, have been associated with an increased risk of car-
diac valvular disease, pleuropulmonary ﬁ  brosis and pleural 
effusion thereby limiting their use.18,19 In fact, pergolide was 
recalled by the FDA in 2007 after 19 years on the US market 
citing these safety concerns.
Rarely, anticholinergics, most commonly benztropine 
and trihexyphenidyl, are used in the treatment of early PD. 
Anticholinergics have been shown to have a mild effect on 
PD symptoms, primarily tremor.4 Benztropine is initiated 
at 0.5 mg twice daily and increased by 0.5 to 1.0 mg every 
3 to 4 days as necessary. Trihexyphenidyl is generally 
initiated at 1 mg once or twice daily and increased by 0.5 
to 1.0 mg every 3 to 4 days as necessary. Amantadine has 
also been shown to have a modest effect in early PD.4 It is a 
glutamateric N-methyl-D-aspartate (NMDA) antagonist and 
has been postulated to increase dopamine release, decrease 
the reuptake of dopamine and stimulate dopamine receptors 
although the exact mechanism of action in PD is not entirely 
clear. Amantadine is generally initiated at 100 mg/day and 
increased up to 300 mg/day as necessary. Although higher 
doses can be used, it is not recommended due to an increase 
in adverse effects such as confusion and hallucinations.8
Treatment of advanced Parkinson’s 
disease
There are multiple treatment options available for advanced 
PD patients that develop levodopa-induced motor ﬂ  uctua-
tions and dyskinesia.7,8 One approach is to adjust the dosage 
or dosing frequency of levodopa or to switch to an extended 
release formulation of levodopa. However, several studies 
have demonstrated that the extended release formulation 
of levodopa does not reduce “off” time compared to the 
immediate release formulation.7 Another approach is to add 
an adjunctive therapy to levodopa such as amantadine, an 
MAO-B inhibitor, a COMT inhibitor, and/or a dopamine 
agonist.
Amantadine has been shown to be effective in reducing 
dyskinesia.7 In a double-blind study, amantadine (100 mg 
twice daily) was shown to reduce dyskinesia by 24%.20 
Although not available in the US, an intravenous formula-
tion of amantadine (amantadine sulfate) has been shown to 
reduce dyskinesia by up to 50% after an infusion of 200 mg 
compared to placebo.21
The MAO-B inhibitors, selegiline, orally disintegrating 
selegiline and rasagiline are approved as adjunct treatments to 
levodopa. Selegiline is generally given twice daily with 5 mg 
taken in the morning and afternoon. There are insufﬁ  cient 
data on the effects of selegiline on motor complications and it 
has been concluded that it may possibly reduce motor ﬂ  uctua-
tions.7 Orally disintegrating selegiline is a newer formulation 
of selegiline which has fewer amphetamine metabolites and 
eliminates the need for swallowing pills. It is approved for 
the treatment of patients with levodopa-induced wearing off 
and has been shown to reduce “off” time by 2.2 hours per day 
compared to 0.6 hours with placebo.22 Orally disintegrating 
selegiline is initiated at 1.25 mg once daily and increased 
after 6 weeks if needed to 2.5 mg once daily. The American 
Academy of Neurology (AAN) evidence-based review of 
treatment options for motor ﬂ  uctuations concluded that 
rasagiline was effective in reducing “off” time and should 
be offered as a treatment option. Reductions in daily “off” 
time ranged between 0.5 and 1.0 hours per day depending 
on the dose of rasagiline.7 In advanced PD, rasagiline is 
initiated at 0.5 mg once daily and increased to 1.0 mg once 
daily as needed.
COMT inhibitors are another adjunctive option for the 
treatment of advanced PD. The enzyme COMT breaks down 
levodopa; therefore, the addition of a COMT inhibitor allows 
more levodopa to reach the brain. Entacapone and tolcapone 
are the COMT inhibitors available for the treatment of 
advanced PD and they are used only in conjunction with 
levodopa. The AAN evidence-based guidelines concluded 
that entacapone is effective in reducing “off” time an average 
of 0.7 to 1.2 hours per day and should be offered to patients 
with motor ﬂ  uctuations.7 Entacapone is available in 200 mg 
tablets. One tablet is given with each dose of levodopa, 
not to exceed a total daily dose of 1600 mg of entacapone. 
Entacapone is also available in a triple combination tablet 
containing carbidopa, levodopa and entacapone. There are six 
strengths of the triple combination available in which each Clinical Interventions in Aging 2009:4 182
Nashatizadeh et al
tablet contains 200 mg of entacapone and either 50, 75, 100, 
125, 150 or 200 mg of levodopa and carbidopa equivalent 
to one quarter of the levodopa dose. Tolcapone has been 
determined to be probably effective in the treatment of “off” 
time with an average daily reduction in “off” time of 0.9 to 
1.8 hours.7 It was also noted that tolcapone should be used 
with caution due to potential hepatotoxicity and requires 
regular safety monitoring. Tolcapone is initiated at 100 mg 
three times daily and increased to 200 mg three times daily if 
necessary. If there is no reduction in “off” time after 3 weeks 
of tolcapone therapy it should be discontinued.
The dopamine agonists pramipexole and ropinirole 
have been determined to probably be effective in reducing 
“off” time and should be considered as a treatment option.7 
Pramipexole has been shown to reduce “off” time by an 
average of 12% to 24% and ropinirole by an average of 7% to 
19%. Both medications are generally given three times daily 
for advanced PD with a maximum daily dose of 4.5 mg of 
pramipexole and 24 mg of ropinirole. The rotigotine patch 
is not approved for advanced PD in the US; however, out-
side of the US it is approved at dosages up 16 mg/24 hours. 
Rotigotine 8 mg/24 hours was shown to reduce “off” time 
by 1.8 hours a day and the 12 mg/24 hour dose by 1.2 hours 
a day.23 Cabergoline, a once-daily, ergot dopamine agonist, 
has been shown to reduce “off” time by 18%.7 Apomorphine 
is the only injectable medication approved for the treatment 
of PD. It is a fast-acting, short-duration treatment used for 
advanced PD as a rescue therapy for patients with severe 
“off ” periods and has been shown to reduce daily “off” time 
by an average of 2 hours.24
A common problem in early and advanced PD is patient 
medication compliance. In early disease, patients generally 
initially receive beneﬁ  t from their treatment regimen in 
spite of late or missed doses of medication. As the disease 
progresses, multiple medications are often prescribed with 
more complicated dosing schedules and in order to maintain 
beneﬁ  t and avoid motor complications, adherence to the 
prescribed dosing schedule becomes an important issue. In 
a 4-week study of medication compliance in PD patients 
with a dosing schedule requiring the intake of medication at 
least three times daily, only 10% of the patients had com-
plete compliance. Furthermore, it was reported that 51% of 
the patients missed at least one dose a week, 21% missed at 
least three doses per week and 82% of patients did not take 
their medication on time.25 The most common reasons for 
non-compliance were forgetting to take their medication or 
not having access to their medication at the scheduled dos-
ing time. Medication compliance was also measured in a 
larger multicenter study of 112 PD patients using electronic 
monitoring bottles.26 The median overall compliance for tak-
ing the amount of medication prescribed was 97.7%, compli-
ance for taking the medication on the right day was 86.2% 
and compliance for taking it at the right time was 24.4%. It 
was also shown that those with suboptimal compliance had 
worse motor scores and those taking once-daily prepara-
tions had better compliance than those taking multiple daily 
doses. This study highlights the need for medications with 
less complicated dosing schedules with fewer daily doses. In 
2008, the FDA approved ropinirole prolonged release which 
is a once daily 24-hour formulation of the dopamine agonist, 
ropinirole. This is the ﬁ  rst once-daily oral dopamine agonist 
approved for both early and advanced PD in the US.
Ropinirole
Ropinirole is the active drug in ropinirole prolonged release. 
Ropinirole is a non-ergot D2/D3 dopamine agonist with the 
greatest afﬁ  nity at the D3 receptors.27 It has afﬁ  nity to central 
and peripheral dopamine receptors. Ropinirole is absorbed 
rapidly with peak plasma concentrations occurring in 1 to 
2 hours. After 2 days of use, steady state concentrations are 
generally achieved. The bioavailability is approximately 
55% but absorption may be delayed by an average of 2 hours 
after consuming a meal high in fat compared with the fast-
ing state. Nevertheless, no clinically signiﬁ  cant differences 
in Cmin, Cmax or AUC24 between fasting and fed states have 
been noted.27
Since the pharmacokinetics of ropinirole have not been 
studied in patients with hepatic impairment it should be 
titrated with caution in patients with hepatic insufﬁ  ciency. 
No speciﬁ  c modiﬁ  cations in dosing are necessary in patients 
with mild to moderate renal insufﬁ  ciency as characterized by 
a creatine clearance of 30 to 50 mL/min because only 10% of 
the drug is excreted unchanged in urine. Ropinirole has not 
been studied in patients with severe renal impairment. Plasma 
protein binding is highly variable between 10% and 40% with 
an overall volume of distribution of about 7.5 L/kg.28 The 
elimination half-life of ropinirole is about 6 hours and this 
is mainly through cytochrome P450 metabolism by isozyme 
CYP1A2 and to a lesser extent by isozyme CYP3A.27
Potential interactions 
and special populations
Ciprofloxacin is a second generation fluoroquinolone 
antibiotic and known inhibitor of CYP1A2 that was found 
to increase ropinirole Cmax by about 60% and AUC by 84%. 
Other clinically relevant potential CYP1A2 inhibitors include Clinical Interventions in Aging 2009:4 183
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amiodarone, cimetidine, ﬂ  uvoxamine, interferon, mexilitine 
and ticlopidine. Patients taking ropinirole may require dos-
ing adjustments with the introduction, withdrawal or dose 
adjustment in any of these medications.27
Conversely, smoking cigarettes is known to induce CYP1A2 
thereby reducing Cmax levels by about 30% in comparison with 
non-smokers. High-dose estrogen appears to reduce drug 
clearance by about 35%, so patients who stop taking hormonal 
replacement therapy might require higher doses of ropinirole to 
achieve the same clinical effect.27 Because ropinirole is a dopa-
mine agonist, the concurrent use of dopamine antagonists such 
as neuroleptic medications is likely to be counterproductive and 
diminish the efﬁ  cacy of either type of medication. Ropinirole 
itself does not induce or inhibit the cytochrome P450 system, 
so no signiﬁ  cant drug–drug interactions have been noted or 
are expected with other CYP1A2 substrates.27
Given that a large number of patients with PD who are over 
the age of 65, it is worth noting that the drug is cleared 15% 
less in older patients.27 However, individual dosing titrated to 
effect makes this population comparison between younger and 
older patients less clinically meaningful. Many older patients 
are sensitive to new medications due to physiologic differences 
so special care should be taken to initiate at the lowest dose 
and escalate slowly to reduce adverse effects.
Ropinirole prolonged release
Ropinirole prolonged release is designed as a three-layer 
tablet with the innermost layer containing ropinirole and two 
outer barrier layers containing placebo that help to control 
the amount of surface area available for drug release.29 The 
bioavailability of ropinirole prolonged release compared to 
the immediate release formulation is nearly 100%. After 
approximately 4 days of use, steady state concentrations are 
generally achieved. As would be expected, from a once-daily 
8 mg dose of ropinirole prolonged release, the median time to 
achieve maximum plasma concentration is longer than that 
of the immediate release formulation dosed as 2.5 mg three 
times daily (∼6 hours vs ∼2 hours).29 However, similar steady-
state calculations of the area under the curve for a 24-hour 
period (AUC24) were noted between prolonged release and 
immediate release formulations (16.3 ng × h/mL/mg vs 
16.0 ng × h/mL/mg).30 In addition, similar dose-normalized 
minimum plasma levels were noted between the two 
formulations (0.44 ng/mL/mg vs 0.45 ng/mL/mg). The dose-
normalized Cmax for ropinirole prolonged release is slightly 
lower than the immediate release formulation (0.92 ng/mL/mg 
vs 1.05 ng/mL/mg), most likely resulting from a more gradual 
approximation of peak dose.28
Ropinirole prolonged release is currently available in 
the US in 2 mg, 4 mg, 8 mg, and 12 mg tablets whereas 
ropinirole immediate release is available in 0.25 mg, 0.5 mg, 
1 mg, 2 mg, 3 mg, 4 mg and 5 mg tablets.27,29 When switching 
patients from ropinirole immediate release to ropinirole pro-
longed release, it is important to consider the total daily dose 
of immediate release because it is usually administered mul-
tiple times daily. For example, a ropinirole immediate release 
regimen of 4 mg three times a day would equal a total daily 
dose of 12 mg, which is equivalent to a single 12 mg dose 
of ropinirole prolonged release. Table 2 compares equivalent 
dosing amounts based on the immediate release total daily 
dose.29 Because ropinirole immediate release is available 
in doses less than 1 mg (0.25 and 0.50 mg), conversion to 
prolonged release doses may approximate but may not always 
equal 1:1 dosing. For example, a patient taking immediate 
release 0.75 mg three times a day (total daily dose = 2.25 mg) 
would be recommended to switch to prolonged release 2 mg 
tablet once daily. The prolonged release tablets should never 
be broken into halves because doing so would break down the 
process of gradual drug release resulting in supratherapeutic 
and potentially harmful plasma drug levels. Ropinirole pro-
longed release is initiated at 2 mg once daily and increased 
every 1 to 2 weeks by 2 mg until a therapeutic dose is reached 
or a maximum of 24 mg/day is achieved.
Efﬁ  cacy studies
Early Parkinson’s disease
There are currently limited studies of ropinirole prolonged 
release in the literature. The EASE-PD Monotherapy study 
was a multicenter, randomized, double-blinded, crossover 
study involving ropinirole immediate release and ropinirole 
prolonged release to determine non-inferiority. Participants 
were required to be within Hoehn and Yahr stage I–III and 
Table 2 Conversion from ropinirole immediate release to ropinirole 
prolonged release29
Ropinirole immediate release 
total daily dose (mg)
Ropinirole prolonged 
release daily dose (mg)
0.75–2.25 2
3–4.5 4
66
7.5–9 8
12 12
15–18 16
21 20
24 24Clinical Interventions in Aging 2009:4 184
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not taking levodopa or dopamine agonists for at least two 
weeks prior to the study.31 The only concomitant antiparkin-
sonian medications allowed were stable doses of selegiline, 
amantadine and anticholinergics. After taking placebo 
for 7 days, 161 patients were randomized into four pos-
sible permutations of formulation sequence: 1) immediate 
release – immediate release – prolonged release, 2) imme-
diate release – prolonged release – prolonged release, 
3) prolonged release – prolonged release – immediate release 
and 4) prolonged release – immediate release – immediate 
release. During the first 12-week period, patients were 
given the ﬁ  rst formulation in their sequence such that 50% 
initially received ropinirole immediate release 0.25 mg three 
times daily and the other 50% initially received ropinirole 
prolonged release 2 mg once daily. Over those 12 weeks, 
patient doses were increased and titrated clinically to achieve 
efﬁ  cacy and tolerability up to a maximum of 24 mg daily in 
either formulation.31
After the initial titration period, subjects taking either 
immediate (8.9 points) or prolonged release (10.4 points) 
formulations had overall improvement in their UPDRS motor 
scores but there was no signiﬁ  cant difference in efﬁ  cacy 
between the two formulations. Only patients who achieved 
a stable UPDRS motor score over a 2-week period were 
allowed to proceed to an 8-week maintenance period.31 It 
is important to note that at the end of these 8 weeks, half 
of the patients initially taking ropinirole immediate release 
were switched overnight to the closest available ropinirole 
prolonged release dose. Likewise, half of the patients initially 
taking ropinirole prolonged release were switched overnight 
to the closest available ropinirole immediate release dosing 
regimen. The remaining patients underwent a dummy switch 
overnight and therefore remained on the same medication 
they were already taking. After a second 8-week maintenance 
period, a similar switch took place whereby this time anyone 
who had actually switched drugs previously was given a 
dummy switch overnight, and those who had the dummy 
switch previously changed to the alternate formulation of 
drug. In this way, by the end of the second 8-week mainte-
nance period, all participants had successfully been switched 
to the alternate formulation (50% after the ﬁ  rst maintenance 
period and the other 50% after the second period).
A total of 114 subjects completed the study.31 Subjects 
initially titrated on ropinirole prolonged release were able to 
begin with a higher total daily dose (2 mg instead of 0.75 mg) 
and achieve the maximum daily dose of 24 mg with fewer 
dose titrations (minimum 8 dose titrations) compared to those 
on immediate release (minimum 13 dose titrations). Only ﬁ  ve 
patients taking ropinirole immediate release required the 
next higher dose of ropinirole prolonged release after being 
switched to maintain efﬁ  cacy. Similarly, only two patients 
taking ropinirole prolonged release required the next higher 
dose of ropinirole immediate release after switching. No dose 
reductions were performed because of adverse effects. The 
overall mean change in UPDRS motor scores was a clinically 
insigniﬁ  cant worsening of 0.6 points in the ropinirole imme-
diate release group and a clinically insigniﬁ  cant improvement 
of 0.1 points for the ropinirole prolonged release group noted 
throughout the three 8-week maintenance periods suggest-
ing that similar doses have similar efﬁ  cacy.31 Inferiority 
was based on a predeﬁ  ned UPDRS motor score difference 
between the immediate release and prolonged release groups 
of at least three points on the UPDRS motor subscale. 
Therefore, ropinirole prolonged release was concluded to be 
non-inferior to ropinirole immediate release. There were no 
signiﬁ  cant differences between groups in UPDRS activities 
of daily living (ADL), Beck Depression Inventory scores, 
Epworth Sleepiness Scale scores or Parkinson’s Disease 
Sleep Scale scores. It is important to mention that overall 
medication compliance was signiﬁ  cantly better in those 
taking ropinirole prolonged release (97%) compared to rop-
inirole immediate release (88%–92%; p  0.01).
The authors concluded that ropinirole prolonged release 
was not inferior to ropinirole immediate release and that it 
was a safe and effective treatment for early PD. They also 
demonstrated that an overnight switch with an approximate 
1:1 conversion ratio from ropinirole immediate release to 
ropinirole prolonged release was well tolerated.
Advanced Parkinson’s disease
The EASE-PD Adjunct study was a multicenter, randomized, 
double-blinded, placebo-controlled trial that examined the 
use of once-daily ropinirole prolonged release or placebo for 
24 weeks in 393 patients with idiopathic PD inadequately 
controlled by levodopa.32 Participants were required to 
be within Hoehn and Yahr stage II–IV, to be on a stable 
dose of levodopa for the preceding 4 weeks and to have 
at least 3 hours of daily “off” time during normal waking 
hours. Patients were also allowed to take amantadine, 
anticholinergic medications, COMT inhibitors and/or sele-
giline as long as no changes in dosing were made within 4 
weeks prior to study participation.
All participants received placebo for 14 days and were 
then randomized to receive either once-daily ropinirole pro-
longed release (202 subjects) or to continue taking placebo 
(191 subjects).32 Initial study medication doses of 2 mg were Clinical Interventions in Aging 2009:4 185
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gradually titrated to an effective therapeutic response or the 
development of adverse effects. All patients were titrated 
to a minimum of 6 mg/day and 50% were maintained at the 
study’s maximum dose of 24 mg/day. There was a manda-
tory reduction in levodopa dose once patients reached a 
daily study medication dose of 8 mg. The primary endpoint 
was the mean change from baseline at week 24 in overall 
awake time spent “off” as measured by reviewing patient 
diaries. The mean ﬁ  nal dose of ropinirole prolonged release 
was 18.8 mg/day. Ropinirole prolonged release signiﬁ  cantly 
decreased the average “off” awake time by 2.1 hours daily 
compared to 0.3 hours daily by placebo, which results in an 
adjusted treatment effect of 1.7 fewer “off” hours a day with 
ropinirole prolonged release. UPDRS motor scores were 
improved by 6.5 points with ropinirole prolonged release 
compared to 1.7 points with placebo (p  0.0001).
The study allowed levodopa doses to be reduced based 
on each individual’s clinical improvement as is commonly 
encountered among patients on combination therapy with 
levodopa and a dopamine agonist. At week 24, dose reduc-
tion in levodopa was more common in those receiving rop-
inirole prolonged release (278 mg/day reduction) therapy 
than placebo (164 mg/day reduction).32 Of note, a signiﬁ  cant 
reduction in “off” time was noted as early as week two using 
a 4 mg daily dose of ropinirole prolonged release. More sub-
jects taking active drug were considered to be “very much 
improved” or “much improved” as rated by the Clinical 
Global Impression-Improvement (CGI-I) scale by week 24 
than placebo (42% vs 14%).32
Several significant secondary endpoints were noted 
including signiﬁ  cant improvements in ADL as measured by 
the UPDRS ADL score (3.5 points for ropinirole prolonged 
release vs 0.9 points for placebo; p  0.0001) and a signiﬁ  cant 
reduction in depression as assessed by the Beck Depression 
Inventory II (BDI-II) scale (2.1 points for ropinirole prolonged 
release vs 0.5 points for placebo; p  0.01). There were also 
signiﬁ  cant improvements in several aspects of quality of 
life as measured by the Parkinson’s Disease Quality of Life 
Questionnaire-39 (PDQ-39); These included the subscores of 
mobility (p  0.0001), activities of daily living (p  0.0001), 
emotional well-being (p  0.015), stigma (p  0.02), and 
communication (p  0.02).32 There were no significant 
changes in PDQ-39 subscales of social support, cognition or 
bodily discomfort.
Ropinirole prolonged release was demonstrated to be a safe 
and effective treatment as an adjunct to levodopa for patients 
with advanced PD which allowed for a signiﬁ  cant reduction 
in daily “off” time and a reduction in daily levodopa dose. 
In addition, it was demonstrated that ropinirole prolonged 
release not only improved the motor symptoms of PD com-
pared to placebo but also the non-motor symptoms of the 
disease such as depression and quality of life.32
Adverse effects
In the early PD study, adverse effects were similar between 
ropinirole prolonged and immediate release formulations. The 
adverse events that occurred in greater than 5% of subjects in 
either treatment group included nausea (19% prolonged release, 
20% immediate release), somnolence (11% prolonged release, 
15% immediate release), dizziness (6% prolonged and immedi-
ate release), headache (6% prolonged release, 5% immediate 
release), constipation (5% prolonged and immediate release), 
dyspepsia (3% prolonged release, 7% immediate release) and 
fatigue (3% prolonged release, 5% immediate release).31
In the advanced PD study, the most common adverse 
effects noted with ropinirole prolonged release versus placebo 
included the development of dyskinesia (13% vs 3%), nausea 
(11% vs 4%), dizziness (8% vs 3%), somnolence (7% vs 4%), 
hallucinations (6% vs 1%), and orthostatic hypotension 
(5% vs 2%).32 Withdrawal rates from the EASE-PD Adjunct 
study were comparable between ropinirole prolonged release 
and placebo, with 5% of each group withdrawing from the 
study. Although ropinirole may worsen pre-existing dyskinesia 
or increase the development of dyskinesia in patients with PD, 
dyskinesia can often be managed by decreasing the concomitant 
dose of levodopa. It is worth noting that 48% of the 27 advanced 
PD trial participants who reported dyskinesia at any time dur-
ing the study had already reported their presence at baseline.32 
No signiﬁ  cant changes in supine blood pressure were noted in 
subjects participating in clinical trials.29
Conclusion
There are several potential advantages in using ropinirole 
prolonged release versus the immediate release formulation, 
especially during the more advanced stages of PD. Many 
patients with motor ﬂ  uctuations cycle between “on” and “off” 
states so maintaining more consistent dopaminergic activity 
using ropinirole prolonged release could alleviate or potentially 
even delay the onset of these ﬂ  uctuations. Furthermore, slower 
absorption and steadier plasma levels with ropinirole prolonged 
release are likely to increase tolerability by reducing adverse 
effects associated with the more marked peak and troughs of 
the immediate release formulation. In addition, the simpler 
titration schedule may allow the patient to achieve clinically 
desired results more quickly than with the immediate release 
formulation.31 Once-daily instead of multiple divided doses is Clinical Interventions in Aging 2009:4 186
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also likely to increase patient compliance as most patients with 
PD are already on a complicated regimen.
Ropinirole prolonged release appears to be a safe, well-toler-
ated option for treating early and advanced PD. This medication 
has a wide spectrum of use in PD and can include patients who 
need initial monotherapy, those insufﬁ  ciently controlled by 
levodopa, and those already taking a dopamine agonist with 
motor ﬂ  uctuations related to variations in plasma levels. Patients 
who are prescribed this medication are more likely to witness 
objective improvement in motor function as well as subjective 
improvement in ADL, several important aspects regarding qual-
ity of life, and possibly even depression. Several pending studies 
will likely elaborate more on comparisons between immediate 
and prolonged release forms of ropinirole although the adverse 
effect proﬁ  les appear to be similar. Because immediate release 
ropinirole is approved for restless legs syndrome, further studies 
using ropinirole prolonged release in restless legs syndrome are 
also likely in the future.
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